Levothyroxine Treatment Adequacy and Formulation Changes in Patients with Hypothyroidism: A Retrospective Study of Real-World Data from the United States
Study context
- Population
- Adults with hypothyroidism receiving levothyroxine (LT4), Optum Clinical and Claims Database, March 2013 through February 2020, observed ≥12 months
- Participants
- 11,259 vs 25,076
- Exposure
- TSH-indexed vs LT4-indexed
- TSH-indexedn = 11,259
- LT4-indexedn = 25,076
- Outcome
- Proportion with low, normal or high TSH (<0.45, 0.45-4.5, >4.5 mIU/L) and proportion switching LT4 formulations
Methodological detailsreal-world claims data, descriptive statistics
- Real-world claims data
- Descriptive statistics
Main finding
As reported in the abstract
Normal TSH
TSH-indexed
81.1%
9130 of 11,259
- ≥1 LT4 formulation switch in 12 months, LT4-indexed (N = 6238)
- 24.9%
- ≥1 formulation switch in up to 24 months (N = 10,370)
- 41.4%
Observational data: associations, not effects.
Further findings
Formulation switch by insurance type · significantly higher with Medicare
P < 0.001
Normal mean TSH by age group, sex and insurance type · follow-up
- Patients with normal mean TSH in each subgroup
- ≥70%
Switched only once, among those switching in 12 months
- Switched only once
- 67.3%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Levothyroxine Treatment Adequacy and Formulation Changes in Patients with Hypothyroidism: A Retrospective Study of Real-World Data from the United States. Thyroid. Published 6 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →